Beware renal adverse effects of anti-vascular endothelial growth factor treatmentBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3838 (Published 01 June 2012) Cite this as: BMJ 2012;344:e3838
- Lindsay Keir, MRC clinical research training fellow1,
- Feike van Moorsel, MSc student2,
- Moin A Saleem, professor of paediatric renal medicine3,
- Anna Richards, Wellcome Trust intermediate clinical fellow4
- 1Academic Renal Unit, University of Bristol, Southmead Hospital, Bristol, UK
- 2Pharmaceutical Science, Utrecht University, Utrecht, Netherlands
- 3Children’s Renal Unit, Bristol Royal Hospital for Children, Bristol, UK
- 4MRC/University of Edinburgh Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh EH16 4TJ, UK
Treatment based on antibodies to vascular endothelial growth factor (VEGF) has dramatically improved the management of wet age related macular degeneration.1 The debate surrounding the off label use of bevacizumab versus ranibizumab raised many issues. However, we were worried by the lack of a caution regarding the potential renal side effects associated with this class of drugs.
VEGF is important in maintaining renal glomerular integrity and …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial